Pharmacy services

Tender description

University College London Hospitals NHS Foundation Trust is looking to establish a single supplier framework agreement to deliver a fully integrated radiopharmacy services and consumables. The framework agreement will consist of 3 lots: — Lot 1: UCLH Managed Services, — Lot 2: Managed Services, — Lot 3: Radiopharmaceutical Consumables. University College London Hospitals NHS Foundation Trust (the ‘Authority’), is issuing this tender in connection with a competitive with negotiation procedure procurement for the provision of a framework agreement for nuclear medicine radiopharmacy services and consumables for University College London Hospitals NHS Foundation Trust (the ‘Contract’), and the subsequent call-off of Radiopharmacy Services and Consumables (the ‘Call-Offs’) from the Contract by the Authority. This procurement and resulting single supplier framework agreement contains 3 lots: Lot 1: UCLH Managed Services; Lot 2: Managed Services; Lot 3: Radiopharmaceutical Consumables. The highest scoring supplier will be awarded all 3 lots, resulting in a single supplier framework agreement. Where the Authority wishes to call-off from this framework agreement, a separate Contract will be entered into for the services under each lot. Where the Authority wishes to call-off from this framework agreement, a separate Contract will be entered into for the services under each lot. The framework agreement will be available to the Authority and all other NHS Trusts. For a detailed list of all NHS Trusts please see https://www.nhs.uk/servicedirectories/pages/nhstrustlisting.aspx UCLH provides first-class acute and specialist services in 6 hospitals in central London. Our mission is to deliver top-quality patient care, excellent education and world-class research. In partnership with University College London (UCL) we are 1 of the country’s 5 comprehensive biomedical research centres. We are a member of UCL partners which brings together some of the UK's world-renowned medical research centres and hospitals. UCLH employs over 8 800 staff, has approximately 1 161 beds across all its sites with approximately 160 000 inpatient admissions and 950 000 outpatient appointments per annum. During 2019 and 2020 UCLH will be opening 2 new hospital sites: — opening in September 2019, a specialist centre for services currently at the Eastman Dental and Royal National Throat Nose and Ear Hospitals, — opening in 2020, a new facility which includes Europe’s largest centre for blood disorders, short stay surgery and a national proton beam therapy centre. Further information relating to the non-PFI estate can be found in the data pack issued with this ITPN and in the service matrix. The Institute of Nuclear Medicine (INM) carries out radionuclide imaging investigations and therapies for the purposes of clinical diagnosis, treatment and research. It is the largest single site department in the UK and currently undertakes some 17 000 studies per annum. INM provide a wide range of ‘state of the art’ nuclear medicine imaging services including: — general nuclear medicine including in-vitro tests, — Single-Photon Emission Computed Tomography (SPECT)/with x-ray Computed Tomography (CT) (SPECT/CT), — ultra-fast dedicated cardiac SPECT, — Positron Emission Tomography/Computed Tomography (PET/CT), — Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) (first in the UK). In addition, INM also perform a range of routine and experimental inpatient and outpatient radionuclide therapy procedures, with access to 10 dedicated radionuclide therapy beds. The Authority is looking to enter into a new Contract that is able to provide an innovative and flexible approach. It is seen as imperative that there is an on-site element to this Contract in order to maintain an efficient and effective working partnership with tangible benefits for both parties. In particular certain isotopes would continue to benefit form on site production due to their limited shelf life.